Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 228

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties

Open access
Hegedűs, C, Özvegy‐Laczka, C, Apáti, Á, Magócsi, M, Német, K, Őrfi, L, Kéri, G, Katona, M, Takáts, Z, Váradi, A, Szakács, G, Sarkadi, B·2009·British Journal of Pharmacology

Abstract

Background and purpose: ABC multidrug transporters (MDR‐ABC proteins) cause multiple drug resistance in cancer and may be involved in the decreased anti‐cancer efficiency and modified pharmacological properties of novel specifically targeted agents. It has been documented that ABCB1 and ABCG2 interact with several first‐generation, small‐molecule, tyrosine kinase inhibitors (TKIs), including the Bcr‐Abl fusion kinase inhibitor imatinib, used for the treatment of chronic myeloid leukaemia. Here, we have investigated the specific interaction of these transporters with nilotinib, dasatinib and bosutinib, three clinically used, second‐generation inhibitors of the Bcr‐Abl tyrosine kinase activity. Experimental approach: MDR‐ABC transporter function was screened in both membrane‐ and cell‐based (K562 cells) systems. Cytotoxicity measurements in Bcr‐Abl‐positive model cells were coupled with direct determination of intracellular TKI concentrations by high‐pressure liquid chromatography‐mass spectrometry and analysis of the pattern of Bcr‐Abl phosphorylation. Transporter function in membranes was assessed by ATPase activity. Key results: Nilotinib and dasatinib were high‐affinity substrates of ABCG2, and this protein mediated an effective resistance in cancer cells against these compounds. Nilotinib and dasatinib also interacted with ABCB1, but this transporter provided resistance only against dasatinib. Neither ABCB1 nor ABCG2 induced resistance to bosutinib. At relatively higher concentrations, however, each TKI inhibited both transporters. Conclusions and implications: A combination of in vitro assays may provide valuable preclinical information for the applicability of novel targeted anti‐cancer TKIs, even in multidrug‐resistant cancer. The pattern of MDR‐ABC transporter–TKI interactions may also help to understand the general pharmacokinetics and toxicities of new TKIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2009.00383.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 228

Metadata

Authors
Hegedűs, C., Özvegy‐Laczka, C., Apáti, Á., Magócsi, M., Német, K., Őrfi, L., Kéri, G., Katona, M., Takáts, Z., Váradi, A., Szakács, G., & Sarkadi, B.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2009-10
Volume
158
Issue
4
Pages
1153-1164
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1546346721
Cited by
228
References
3
FWCI
8.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties. https://app.cochat.ai/papers/10.1111/j.1476-5381.2009.00383.x
The paper
Hegedűs, C., Özvegy‐Laczka, C., Apáti, Á., Magócsi, M., Német, K., Őrfi, L., Kéri, G., Katona, M., Takáts, Z., Váradi, A., Szakács, G., & Sarkadi, B. (2009). Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2009.00383.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.